Cambridge Healthtech Instituteの初開催

Single-Cell Multiomics
(シングルセルマルチオミクス)

シングルセルトランスクリプトミクス、ゲノミクス、プロテオミクス、メタボロミクス

2023年3月7 - 8日、PST(米国太平洋標準時)

 

ゲノミクス、エピゲノミクス、トランスクリプトミクス、プロテオミクス、メタボロミクスのデータによるシングルセル解析は、システム生物学の次なるフロンティアを可能にすることが期待されています。シングルセルの解像度でのマルチオミクスプロファイリングは、生態と細胞の不均一性の理解を変革し、新しいターゲットやバイオマーカーの発見と精密医療の発展を促進します。CHIの初開催「シングルセルマルチオミクス」会議では、シングルセルマルチオミクスプロファイリングとデータ解釈の技術、医薬品開発とトランスレーショナルリサーチへの応用について取り上げます。

3月7日(火)

SINGLE-CELL SPATIAL BIOLOGY
シングルセル空間生物学

2:00 pm

Chairperson's Remarks

Akil Merchant, MD, PhD, Associate Professor, Medicine & Director, Imaging Mass Cytometry Core, Cedars-Sinai Medical Center

2:05 pm

Spatially-Resolved Single-Cell Biomarkers in Lymphoma

Akil Merchant, MD, PhD, Associate Professor, Medicine & Director, Imaging Mass Cytometry Core, Cedars-Sinai Medical Center

Spatially-resolved single-cell analysis of lymphoma identifies markers of therapeutic resistance. Molecular subtypes that associate with changes in the tumor architecture will be presented. Comparison between immune checkpoint response and resistant lymphoma identify potential biomarkers of treatment response. Implications for engineered cellular therapies such as CAR T will be discussed.

2:35 pm

AI-Enabled Single-Cell Spatial Biology Technologies with Image-Guided FACS

Yuhwa Lo, PhD, Professor, Electrical & Computer Engineering, University of California, San Diego

To help obtain both intracellular and intercellular spatial information and produce a linkage between phenotypes and genotypes of cells, we developed technologies of image-guided cell sorters based on 3D imaging flow cytometers capable of producing cell tomography at a throughput of 1000 cells/s. With the AI capabilities with real-time AI inference, the systems have shown superb capabilities for classification, cell type discovery, and spatial biology studies.

3:05 pm

Single-Cell Spatial Omics Journey to Signaling and Metabolism in situ

Ahmet Coskun, PhD, Assistant Professor, Biomedical Engineering, Georgia Institute of Technology

In this talk, I will introduce multiplex imaging modalities (genomics, proteomics, and metabolomics) to decipher the spatial and temporal decision-making of single-cells at macromolecular resolution in engineered organoids and human tissues for systems immuno-engineering, subcellular precision oncology, and personalized regenerative medicine applications. Automated machine learning algorithms in this single-cell big data impact biomedical practice and clinical care. In the last part of the talk, digital technologies interfacing cellular interactive media will be presented using the virtual reality of 3D spatial omics. Single-cell biotechnologies and digital cellular media tools synergistically complement each other for next-generation bioengineering, crowd-sourced education, and collaborative discovery platforms.

3:35 pm High resolution mapping of the breast cancer tumor microenvironment using single cell, spatial, and in situ analysis

Joshua Talboom, PhD, Science & Technology Advisor, 10x Genomics

Refreshment Break in the Exhibit Hall with Poster Viewing4:05 pm

PLENARY KEYNOTE SESSION: MULTI-CANCER EARLY DETECTION
基調講演・プレナリーセッション:多重がんの早期発見

4:45 pm

Chairperson's Remarks

Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium

Sponsored Presentation (Opportunity Available)4:50 pm

5:00 pm PANEL DISCUSSION:

Evaluation and Implementation of Multi-Cancer Early Detection Tests

PANEL MODERATOR:

Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium

Multi-cancer early detection promises to improve cancer diagnosis, treatment and patient care. However, introducing MCED technologies into clinical care requires evaluation and assessment of benefits and risks, potential outcomes, costs, and value. The multi-stakeholder expert panel will address how MCED will impact clinical care, outstanding challenges in evidence generation, test reimbursement, market adoption, and equitable patient access.

PANELISTS:

Philip E. Castle, PhD, Director, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health

Tomasz Beer, MD, CMO, Multi-Cancer Early Detection, Exact Sciences

Omar Perez, PhD, Head, Medical Diagnostics, AstraZeneca

Megan P. Hall, PhD, Vice President, Medical Affairs, GRAIL LLC

Hakan Sakul, PhD, Vice President and Head, Diagnostics, Pfizer, Inc.

Close of Day5:45 pm

3月8日(水)

Registration and Morning Coffee7:30 am

30th ANNIVERSARY OF TRI-CON PLENARY KEYNOTE SESSION: DIAGNOSTICS INNOVATION AND INVESTMENT TRENDS
30周年記念TRI-CON基調講演・プレナリーセッション:診断イノベーションと投資動向

8:00 am

Chairperson's Remarks

Tom Miller, Founder & Managing Partner, GreyBird Ventures, LLC

8:15 am KEYNOTE PRESENTATION:

Failure: The Best Way to Learn

Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation

The thought of failure creates fear. The reality of failure creates opportunity. We must embrace failure and all it can teach. As Arianna Huffington said: “Failure is not the opposite of success - it’s part of success.” We will discuss how to think differently about failing - how to motivate yourself and your teams.

8:30 am PANEL DISCUSSION:

Diagnostics Innovation and Investment Trends

PANEL MODERATOR:

Tom Miller, Founder & Managing Partner, GreyBird Ventures, LLC

Diagnostics investing experts will review what is hot and what is not in the field. Technological trends and white spaces will be identified, and entrepreneurs will be given best practices to maximize chances for successful financing. The panel will also provide guidance to founders to optimize operational success post-financing and what to do in the event of a stumble, the dreaded pivot, or in dealing with failure.

PANELISTS:

Ajit Singh, PhD, Partner, Artiman Ventures

Nathan Davis, Analyst, RA Capital Management

John W. Czajka, PhD, MBA, Director, Strategy and Innovation, BD Integrated Diagnostic Solutions

Bruce J. Tromberg, PhD, Director, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health; Lead, NIH’s Rapid Acceleration of Diagnostic Technologies (RADx Tech) Program

Mara G. Aspinall, Managing Director, BlueStone Venture Partners; Professor of Practice, Arizona State University; Advisor, The Rockefeller Foundation

Transition to Sessions9:15 am

SINGLE-CELL MULTI-OMIC PROFILING
シングルセルマルチオミクスプロファイリング

9:20 am

Chairperson's Remarks

Namit Kumar, PhD, Principal Scientist, Computational Biology, Bristol Myers Squibb Co.

9:25 am

Next-Generation Biomarkers with Multiplex Immunofluorescence: Astronomy Informs Pathology

Janis Taube, MD, Professor, Dermatology and Pathology, Johns Hopkins University School of Medicine

Using the data architecture for the Sloan Digital Sky Survey, we have recently developed a platform which allows for multiplex immunofluorescence (mIF) histopathologic maps at single cell resolution across whole slides named ‘AstroPath.' This technology is applied to the whole slide mIF mapping of samples from pre- and on-treatment samples from patients treated with immune checkpoint inhibitors (ICIs), enabling the development of biomarkers of response and resistance to ICIs.

9:55 am

Elucidating the Cellular States of Immune Cells Regulating Anti-PD1 Response Using Multi-Omics Single-Cell Sequencing

Namit Kumar, PhD, Principal Scientist, Computational Biology, Bristol Myers Squibb Co.

Immune checkpoint blockade therapies have drastically improved patient survival in numerous cancer types, yet only a subset of patients respond favorably. Current study uses a multi-omics (integrated scRNA and scTCR sequencing) approach to identify distinct cellular states of CD8+ T cells and develop predictive signatures with clinical benefit identified using retrospective analysis. Intended impact of this study is to develop predictive gene signatures from preclinical models which could help improve patient selection in clinical trials and ultimately enhance patient benefit.

10:25 am Scaling Up Single Cell Genomics with Split Pool Combinatorial Barcoding

Charlie Roco Lyons, Cofounder, CTO, Parse Biosciences

This talk will dive into how the power of high throughput single cell profiling on Evercode can be used to accelerate your research.  With the ability to scale up to 1 million cells or nuclei across up to 96 samples at a time means you no longer need to compromise on experimental design.

Coffee Break in the Exhibit Hall with Poster Viewing10:55 am

SINGLE-CELL MULTI-OMIC PROFILING (CONT.)
シングルセルマルチオミクスプロファイリング(続き)

11:35 am

Chairperson's Remarks

Namit Kumar, PhD, Principal Scientist, Computational Biology, Bristol Myers Squibb Co.

11:40 am

Harnessing Single-Cell Multi-Omics for Therapeutic Targeting or MoA Discovery

Chi-Ming Li, PhD, Senior Principal Scientist, Therapeutic Discovery, Amgen

Single-cell sequencing is a quantitative technology frequently used to position or classify cell characteristics based on multiple molecular features. We have utilized such a cutting-edge tool to build our internal disease landscapes and, by cross-comparing with the data generated from in vitro and in vivo models, also provided informative insights in understanding disease biology and revealing potential MoA of proposed or tested therapeutic target. Through the practice, the therapeutic strategy should be able to be carefully proposed or polished.

12:10 pm

Proteomic Mapping of Pulmonary Arteries in Pulmonary Arterial Hypertension

Selena Ferrian, PhD, Principal Scientist, Early Clinical Development, Genentech

Developing a successful immunotherapy to reverse pulmonary arterial hypertension (PAH) pathology requires a comprehensive mapping of the immune cell landscape in pulmonary arteries. Our analyses revealed immune microenvironments as well as vessel-immune cell interactions that have allowed us to propose a relationship with the severity of the PAH lesions and to understand how specific immune cells can drive smooth muscle cell proliferation, ultimately guiding therapeutic efforts to regress neointimal cells.

12:40 pm Talk Title to be Announced

Speaker to be Announced

Presentation to be Announced12:55 pm

Session Break1:10 pm

Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own1:15 pm

Refreshment Break in the Exhibit Hall with Last Chance for Poster Viewing1:45 pm

Close of Conference2:25 pm

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
English

カンファレンスプログラム

2023年3月6-7日

Implementing Precision Medicine

Digital Medicine

At-Home & Point-of-Care Diagnostics

Liquid Biopsy

Spatial Biology

2023年3月7-8日

Precision Health

Diagnostics Innovation and Market Access

Infectious Disease Diagnostics

Advanced Diagnostics for Precision Oncology

Single-Cell Multiomics